Cited by 945Telomeres, Telomerase, and SenescenceCancer-related Molecular PathwaysProtein Kinase Regulation and GTPase Signaling

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

Open access
Lin, Athena W., Barradas, Marta, Stone, James C., van Aelst, Linda, Serrano, Manuel, Lowe, Scott W.·1998·Genes & Development

Abstract

Oncogenic Ras transforms immortal rodent cells to a tumorigenic state, in part, by constitutively transmitting mitogenic signals through the mitogen-activated protein kinase (MAPK) cascade. In primary cells, Ras is initially mitogenic but eventually induces premature senescence involving the p53 and p16 INK4a tumor suppressors. Constitutive activation of MEK (a component of the MAPK cascade) induces both p53 and p16, and is required for Ras-induced senescence of normal human fibroblasts. Furthermore, activated MEK permanently arrests primary murine fibroblasts but forces uncontrolled mitogenesis and transformation in cells lacking either p53 or INK4a . The precisely opposite response of normal and immortalized cells to constitutive activation of the MAPK cascade implies that premature senescence acts as a fail-safe mechanism to limit the transforming potential of excessive Ras mitogenic signaling. Consequently, constitutive MAPK signaling activates p53 and p16 as tumor suppressors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.12.19.3008

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The initial response of normal cells to constitutively active oncogenic stimuli is typically hyperproliferation, which appears sensed by cells, triggering senescence.

    “The initial response of normal cells to constitutively active oncogenic stimuli is typically hyperproliferation, which appears to be “sensed” by cells, triggering a senescence phenotype (Lin et al. 1998).”

    From Cellular senescence and its effector programs (2014) · cites this paper as Lin et al. 1998

    In “Oncogenic Ras is initially mitogenic in normal diploid human fibroblasts,” the paper reports that Ras first forces proliferation and only later produces a senescent phenotype. “Role of the MAPK cascade in cell-cycle arrest” describes senescence as a response to excessive MEK/MAPK activity. These passages support the sequence for Ras signaling, but not the broader assertion that normal cells typically respond this way to constitutively active oncogenic stimuli in general. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • OIS was initially described in culture, where ectopic expression of oncogenic HRAS-G12V or its downstream effectors led to premature senescence.

    “OIS was initially described in culture, where the ectopic expression of oncogenic HRAS-G12V, or its downstream effectors paradoxically led to premature senescence [19][20][21] .”

    From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 7

  1. Dimri, G.P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E.E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. 92: 9363-9367.
  2. Dudley, D.T., L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. 92: 7686-7689.
  3. Hirakawa, T. and H.E. Ruley. 1988. Rescue of cells from ras oncogene-induced growth arrest by a second, complement- ing, oncogene. Proc. Natl. Acad. Sci. 85: 1519-1523.
  4. Pumiglia, K.M. and S.J. Decker. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. 94: 448-452.
  5. Samuelson, A.V. and S.W. Lowe. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mu- tants unable to bind the RB-related proteins. Proc. Natl. Acad. Sci. 94: 12094-12099.
  6. Spaargaren, M. and J.R. Bischoff. 1994. Identification of the gua- nine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-Ras, K-ras, and Rap. Proc. Natl. Acad. Sci. 91: 12609-12613.
  7. Van Aelst, L., M. Barr, S. Marcus, A. Polverino, and M. Wigler. 1993. Complex formation between RAS and RAF and other protein kinases. Proc. Natl. Acad. Sci. 90: 6213-6217.

Cited by

Sorted by citations

Authors
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W.
Affiliations
  • Cold Spring Harbor Laboratory (US)
  • University of Alberta (CA)
Corresponding author
Lowe, Scott W.
Venue
Genes & Development
Published
1998-10-01
Volume
12
Issue
19
Pages
3008-3019
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2125547572
Cited by
945
References
9
Citations by year
2026: 21 · 2025: 16 · 2024: 20 · 2023: 21 · 2022: 21 · 2021: 31 · 2020: 19 · 2019: 21 · 2018: 33 · 2017: 29 · 2016: 25 · 2015: 21 · 2014: 40 · 2013: 33 · 2012: 35
Type
posted content
Language
en
Open access
Locations
  • Genes & Development (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Funders
  • National Institutes of Health (5r01ca072982-04)
  • National Cancer Institute (CA72982, CA13106, P01CA013106)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
premature senescence, p53, p16INK4a, MEK, MAPK signaling, Ras, mitogenic signaling, tumor suppressor, cell transformation, fibroblasts, cell cycle arrest, immortalized cells
MeSH terms
Animals, Cell Cycle, Cell Transformation, Neoplastic, Cells, Cultured, Fibroblasts, Humans, Microinjections, Protein-Tyrosine Kinases, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Protein Serine-Threonine Kinases, Calcium-Calmodulin-Dependent Protein Kinases, ras Proteins, Cyclin-Dependent Kinase Inhibitor p16, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review